18.24
Beam Therapeutics Inc stock is traded at $18.24, with a volume of 3.28M.
It is up +7.29% in the last 24 hours and down -21.72% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
See More
Previous Close:
$17.00
Open:
$16.78
24h Volume:
3.28M
Relative Volume:
1.63
Market Cap:
$1.70B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-10.08
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
+7.29%
1M Performance:
-21.72%
6M Performance:
-21.21%
1Y Performance:
-23.68%
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
BEAM
Beam Therapeutics Inc
|
18.24 | 1.70B | 352.57M | -143.01M | -153.40M | -1.81 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
Jul-23-24 | Initiated | H.C. Wainwright | Buy |
Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
Mar-21-23 | Initiated | Bernstein | Mkt Perform |
Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Dec-13-22 | Initiated | Citigroup | Buy |
Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
Apr-28-22 | Initiated | Credit Suisse | Neutral |
Jan-05-22 | Initiated | Guggenheim | Buy |
Oct-19-21 | Initiated | SVB Leerink | Outperform |
Sep-24-21 | Resumed | Stifel | Buy |
Sep-10-21 | Initiated | BofA Securities | Buy |
May-11-21 | Initiated | Redburn | Buy |
May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
Feb-16-21 | Initiated | Wells Fargo | Overweight |
Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
Jan-06-21 | Initiated | Stifel | Hold |
Aug-05-20 | Initiated | William Blair | Outperform |
Mar-02-20 | Initiated | Barclays | Overweight |
Mar-02-20 | Initiated | JP Morgan | Overweight |
Mar-02-20 | Initiated | Jefferies | Buy |
Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga
Recent uptick might appease Beam Therapeutics Inc. (NASDAQ:BEAM) institutional owners after losing 29% over the past year - simplywall.st
How To Trade (BEAM) - news.stocktradersdaily.com
Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last? - MSN
Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance
Cathie Wood's ARK ETF focuses on Beam Therapeutics, Coinbase stock - Investing.com
Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal - streetwisereports.com
Share Price Appreciation of Biotech Due Over Next Six Months - streetwisereports.com
H.C. Wainwright maintains $80 target on Beam Therapeutics stock By Investing.com - Investing.com India
Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease - AOL.com
H.C. Wainwright maintains $80 target on Beam Therapeutics stock - Investing.com
Beam Therapeutics Presents Additional Data for BEAM-302 in - GlobeNewswire
Beam Presents Addl. Data From Phase 1/2 Trial Of BEAM-302 In Alpha-1 Antitrypsin Deficiency - Nasdaq
Breakthrough: New BEAM-302 Data Shows 91% Success Rate in Rare Liver Disease Treatment - Stock Titan
Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed' - Benzinga
Beam Therapeutics executive sells $55,330 in stock By Investing.com - Investing.com South Africa
Beam Therapeutics executive sells $55,330 in stock - Investing.com Australia
Beam Therapeutics’ chief legal officer sells $104,121 in stock By Investing.com - Investing.com Canada
Beam Therapeutics’ chief legal officer sells $104,121 in stock - Investing.com India
Beam Therapeutics CEO John Evans sells $562,684 in stock By Investing.com - Investing.com India
Beam Therapeutics CEO John Evans sells $562,684 in stock - Investing.com
Beam Therapeutics president sells $136,418 in stock - Investing.com
Beam Therapeutics Executives Sell Shares for Tax Obligations and Personal Sales - TradingView
7 Top Gene-Editing Stocks to Buy | Investing | U.S. News - Money/ US News
Gene Editing: CRISPR Therapeutics vs. Beam Therapeutics - Securities.io
Beam Therapeutics Becomes Oversold - Nasdaq
Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? - Yahoo Finance
8 Best Gene-Editing Stocks to Buy - Insider Monkey
Biotech stocks plunge as FDA’s Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - TradingView
Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles - Investing.com Canada
Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles By Investing.com - Investing.com South Africa
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance - MSN
Beam Therapeutics (BEAM) Upgraded to Buy by Bank of America on P - GuruFocus
Beam Therapeutics (BEAM) Upgraded by BofA on Promising Genetic T - GuruFocus
B of A Securities Upgrades Beam Therapeutics (BEAM) - MSN
Beam upgraded to Buy at BofA Securities on recent genetic condition treatment - Seeking Alpha
Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND By Investing.com - Investing.com South Africa
Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND - Investing.com
This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
B of A Securities Upgrades Beam Therapeutics (BMV:BEAM) - Nasdaq
Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock - Benzinga
BofA raises Beam Therapeutics stock rating to Buy, sets $42 target - Investing.com Canada
BofA raises Beam Therapeutics stock rating to Buy, sets $42 target By Investing.com - Investing.com South Africa
BofA Securities Upgrades Beam Therapeutics to Buy From Neutral - Marketscreener.com
FDA Clears Beam Therapeutics' (BEAM) Drug for Genetic Disease Tr - GuruFocus
Beam Therapeutics gets trial authorization for its genetic disorder treatment in U.S. - Seeking Alpha
Beam Therapeutics New Drug Application for Alpha-1 Antitrypsin Deficiency Gets FDA Clearance - Marketscreener.com
Beam Therapeutics’ BEAM-302 gains FDA’s nod for AATD treatment trial - Investing.com India
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):